Aging and HIV/AIDS: Pathogenetic Role of Therapeutic Side Effects

Overview

Journal Lab Invest

Specialty Pathology

Date 2013 Dec 17

PMID 24336070

Citations 41

Authors

Rebecca A Torres

William Lewis

Affiliations

Soon will be listed here.

Abstract

The intersection of aging and HIV/AIDS is a looming 'epidemic within an epidemic.' This paper reviews how HIV/AIDS and its therapy cause premature aging or contribute mechanistically to HIV-associated non-AIDS illnesses (HANA). Survival with HIV/AIDS has markedly improved by therapy combinations containing nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors, and protease inhibitors (PIs) called HAART (highly active antiretroviral therapy). Because NRTIs and PIs together prevent or attenuate HIV-1 replication, and prolong life, the population of aging patients with HIV/AIDS increases accordingly. However, illnesses frequently associated with aging in the absence of HIV/AIDS appear to occur prematurely in HIV/AIDS patients. Theories that help to explain biological aging include oxidative stress (where mitochondrial oxidative injury exceeds antioxidant defense), chromosome telomere shortening with associated cellular senescence, and accumulation of lamin A precursors (a nuclear envelop protein). Each of these has the potential to be enhanced or caused by HIV/AIDS, antiretroviral therapy, or both. Antiretroviral therapy has been shown to enhance events seen in biological aging. Specifically, antiretroviral NRTIs cause mitochondrial dysfunction, oxidative stress, and mitochondrial DNA defects that resemble features of both HANA and aging. More recent clinical evidence points to telomere shortening caused by NRTI triphosphate-induced inhibition of telomerase, suggesting telomerase reverse transcriptase (TERT) inhibition as being a pathogenetic contributor to premature aging in HIV/AIDS. PIs may also have a role in premature aging in HIV/AIDS as they cause prelamin A accumulation. Overall, toxic side effects of HAART may both resemble and promote events of aging and are worthy of mechanistic studies.

Citing Articles

Lower immune senescence of T cell subsets among virologically suppressed Chinese men who have sex with men living with HIV in comparison with those ART naive.

Li L, Yu F, Yang S, Li H, Tang Y, Ma C BMC Infect Dis. 2025; 25(1):290.

PMID: 40021989 PMC: 11869689. DOI: 10.1186/s12879-025-10511-7.

A Perfect Storm: The Convergence of Aging, Human Immunodeficiency Virus Infection, and Inflammasome Dysregulation.

Thirugnanam S, Rout N Curr Issues Mol Biol. 2024; 46(5):4768-4786.

PMID: 38785555 PMC: 11119826. DOI: 10.3390/cimb46050287.

Oxidative phosphorylation in HIV-1 infection: impacts on cellular metabolism and immune function.

Rodriguez N, Fortune T, Hegde E, Weinstein M, Keane A, Mangold J Front Immunol. 2024; 15():1360342.

PMID: 38529284 PMC: 10962326. DOI: 10.3389/fimmu.2024.1360342.

Elevated Plasma Protein Carbonyl Concentration Is Associated with More Abnormal White Matter in People with HIV.

Riggs P, Anderson A, Tang B, Rubin L, Morgello S, Marra C Viruses. 2023; 15(12).

PMID: 38140650 PMC: 10747698. DOI: 10.3390/v15122410.

Senescent cells at the crossroads of aging, disease, and tissue homeostasis.

Kuehnemann C, Wiley C Aging Cell. 2023; 23(1):e13988.

PMID: 37731189 PMC: 10776127. DOI: 10.1111/acel.13988.

References

Leeansyah E, Cameron P, Solomon A, Tennakoon S, Velayudham P, Gouillou M . Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013; 207(7):1157-65. DOI: 10.1093/infdis/jit006. View

Fontana R . Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009; 49(5 Suppl):S185-95. DOI: 10.1002/hep.22885. View

Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F . Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. EMBO J. 2002; 22(1):131-9. PMC: 140062. DOI: 10.1093/emboj/cdg013. View

Caron M, Auclairt M, Vissian A, Vigouroux C, Capeau J . Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther. 2008; 13(1):27-38. View

Hammer S, Eron Jr J, Reiss P, Schooley R, Thompson M, Walmsley S . Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300(5):555-70. DOI: 10.1001/jama.300.5.555. View

Feng J, Johnson A, Johnson K, Anderson K . Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem. 2001; 276(26):23832-7. DOI: 10.1074/jbc.M101156200. View

Chariot P, Drogou I, Chazaud B, Lombes A, Schaeffer A, Zafrani E . Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol. 1999; 30(1):156-60. DOI: 10.1016/s0168-8278(99)80020-8. View

McKenzie R, Fried M, Sallie R, Conjeevaram H, Di Bisceglie A, Park Y . Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995; 333(17):1099-105. DOI: 10.1056/NEJM199510263331702. View

Huang W, Rha G, Chen L, Seelbach M, Zhang B, Andras I . Inhibition of telomerase activity alters tight junction protein expression and induces transendothelial migration of HIV-1-infected cells. Am J Physiol Heart Circ Physiol. 2010; 298(4):H1136-45. PMC: 2853419. DOI: 10.1152/ajpheart.01126.2009. View

10.

Tennant B, Baldwin B, Graham L, Ascenzi M, Hornbuckle W, Rowland P . Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology. 1998; 28(1):179-91. DOI: 10.1002/hep.510280124. View

11.

Blasco M, Lee H, Rizen M, Hanahan D, Depinho R, Greider C . Mouse models for the study of telomerase. Ciba Found Symp. 1997; 211:160-70; discussion 170-6. DOI: 10.1002/9780470515433.ch11. View

12.

Maagaard A, Holberg-Petersen M, Lovgarden G, Holm M, Pettersen F, Kvale D . Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment. J Infect Dis. 2008; 198(10):1474-81. DOI: 10.1086/592713. View

13.

Aspinall R, Goronzy J . Immune senescence. Curr Opin Immunol. 2010; 22(4):497-9. DOI: 10.1016/j.coi.2010.07.002. View

14.

Ames B, Shigenaga M, Hagen T . Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A. 1993; 90(17):7915-22. PMC: 47258. DOI: 10.1073/pnas.90.17.7915. View

15.

Bokov A, Chaudhuri A, Richardson A . The role of oxidative damage and stress in aging. Mech Ageing Dev. 2004; 125(10-11):811-26. DOI: 10.1016/j.mad.2004.07.009. View

16.

Popper H, Roth L, Purcell R, Tennant B, Gerin J . Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A. 1987; 84(3):866-70. PMC: 304317. DOI: 10.1073/pnas.84.3.866. View

17.

Santos J, Meyer J, Skorvaga M, Annab L, Van Houten B . Mitochondrial hTERT exacerbates free-radical-mediated mtDNA damage. Aging Cell. 2004; 3(6):399-411. DOI: 10.1111/j.1474-9728.2004.00124.x. View

18.

Lennox J . The use of HIV-1 integrase inhibitors in antiretroviral naive patients. Curr Opin HIV AIDS. 2012; 7(5):409-14. DOI: 10.1097/COH.0b013e3283562a27. View

19.

Kohler J, Hosseini S, Cucoranu I, Hoying-Brandt A, Green E, Johnson D . Murine cardiac mtDNA: effects of transgenic manipulation of nucleoside phosphorylation. Lab Invest. 2008; 89(2):122-30. PMC: 2685200. DOI: 10.1038/labinvest.2008.121. View

20.

Johnson A, Ray A, Hanes J, Suo Z, Colacino J, Anderson K . Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem. 2001; 276(44):40847-57. DOI: 10.1074/jbc.M106743200. View